vinflunine vinflunine vinflunine (inn, trade name javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. it was originally discovered by the team of the professor jean-claude jacquesy (umr cnrs 6514 – poitiers university), developed by laboratoires pierre fabre and was licensed to bristol-myers squibb for development in certain countries, including the united states. vinflunineclinical dataahfs/drugs.cominternational drug nameslicense data eu ema: by inn routes ofadministrationintravenousatc codel01ca05 (who) legal statuslegal status eu: rx-only in general: ℞ (prescription only) identifiers iupac name methyl (2β,3β,4β,5α,12β,19α)- 4-(acetyloxy)- 15-indol- 8-yl]- 3-hydroxy- 16-methoxy- 1-methyl- 6,7-didehydroaspidospermidine- 3-carboxylate cas number162652-95-1 ypubchem cid10629256drugbankdb11641 ychemspider8804619 nunii5bf646324kchebichebi:90241 nchemblchembl2110725 ncomptox dashboard (epa)dtxsid30936722 chemical and physical dataformulac45h54f2n4o8molar mass816.944 g·mol−13d model (jsmol)interactive image smiles cc12c=ccn314(cc3)((2oc(=o)c)(c(=o)oc)o)n(c5=cc(=c(c=c45)6(c7c(cn(c7)cc8=c6nc9=cc=cc=c89)c(c)(f)f)c(=o)oc)oc)c inchi inchi=1s/c45h54f2n4o8/c1-8-42-14-11-16-51-17-15-43(36(42)51)30-19-31(34(56-5)20-33(30)49(4)37(43)45(55,40(54)58-7)38(42)59-25(2)52)44(39(53)57-6)21-26-18-27(41(3,46)47)23-50(22-26)24-29-28-12-9-10-13-32(28)48-35(29)44/h9-14,19-20,26-27,36-38,48,55h,8,15-18,21-24h2,1-7h3/t26-,27+,36-,37+,38+,42+,43+,44-,45-/m0/s1 nkey:nmdyywfgpimtko-klcpsuaysa-n n ny (what is this?) (verify) on november 23, 2007, pierre fabre medicament and bristol-myers squibb announced that they were terminating their license agreement for the development of vinflunine, and that pierre fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008." approvals and indications as of 2012, vinflunine was registered for use in australia for "advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum containing regimen," but is not covered under the pharmaceutical benefits scheme. as of 2016, vinflunine was the only commercially-approved agent in some countries for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase iii trial), with a reported median os of about 6 months. clinical trials it has undergone a phase iii clinical trial for advanced transitional cell carcinoma of the urothelial tract.